Great work team! ?? ??
Professor, Oxford University. Visiting Professor, Duke University. Professor Adjunct of Psychiatry, Yale. Co-Chair UK Govt Mental Health Mission.
I was very pleased to join The Wall Street Journal?podcast to reflect on the development of SPRAVATO? (esketamine) for treatment-resistant depression. Its development was a challenging but necessary undertaking. For patients who had exhausted standard treatments, neuroscience needed to think differently. Grounded in early translational science and rigorous clinical evidence, SPRAVATO became the first new mechanism approved for depression in decades. Its approval has helped shift the field from incremental improvements to thoughtful, mechanism-based innovation and intervention. There is much more to be done. But with science, partnership, and urgency, we can—and must—deliver for those facing serious mental illness. https://lnkd.in/emJARKWb